Brilliant Blue has been researched along with Neuralgia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crocetti, L; Dahl, G; Di Cesare Mannelli, L; Ghelardini, C; Giovannoni, MP; Guerrini, G; Lucarini, E; Puglioli, S; Wang, J | 1 |
| Cervetto, C; Di Cesare Mannelli, L; Ghelardini, C; Marcoli, M; Maura, G; Micheli, L; Zanardelli, M | 1 |
2 other study(ies) available for Brilliant Blue and Neuralgia
| Article | Year |
|---|---|
Design and synthesis of the first indole-based blockers of Panx-1 channel.
Topics: Animals; Binding Sites; Connexins; Disease Models, Animal; Drug Design; Humans; Indoles; Male; Membrane Potentials; Mice; Molecular Docking Simulation; Nerve Tissue Proteins; Neuralgia; Oocytes; Oxaliplatin; Structure-Activity Relationship | 2021 |
Oxaliplatin evokes P2X7-dependent glutamate release in the cerebral cortex: A pain mechanism mediated by Pannexin 1.
Topics: Analgesics; Animals; Antineoplastic Agents; Benzenesulfonates; Carbenoxolone; Cell Death; Cell Line, Tumor; Cerebral Cortex; Colonic Neoplasms; Connexins; Glutamic Acid; Humans; Male; Nerve Tissue Proteins; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Purinergic P2X Receptor Antagonists; Pyridines; Rats, Sprague-Dawley; Receptors, Purinergic P2X7; Rosaniline Dyes; Synaptosomes; Tetrazoles | 2015 |